Shibo Jiang

List of Publications by Year in Descending Order

485 papers	25,763 citations	80 h-index	141 g-index
520 ext. papers	30,788 ext. citations	8.8 avg, IF	7.71 L-index

#	Paper	IF	Citations
485	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.. *Cell Research*, **2022**,	24.7	10
484	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells.. *MBio*, **2022**, e0338421	7.8	0
483	Homologous or Heterologous Booster of Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing Antibodies.. *Emerging Microbes and Infections*, **2022**, 1-18	18.9	15
482	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	6
481	Developing pan-□coronavirus vaccines against emerging SARS-CoV-2 variants of concern.. *Trends in Immunology*, **2022**,	14.4	3
480	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant.. *Cell Research*, **2022**,	24.7	2
479	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.. *Cell*, **2022**,	56.2	6
478	Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.. *Frontiers in Cellular and Infection Microbiology*, **2022**, 12, 862754	5.9	
477	Design of artificial □helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114336	6.8	
476	Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41.. *Advances in Experimental Medicine and Biology*, **2022**, 1366, 27-43	3.6	
475	Virus Entry Inhibitors: Past, Present, and Future.. *Advances in Experimental Medicine and Biology*, **2022**, 1366, 1-13	3.6	
474	Peptide-Based HIV Entry Inhibitors.. *Advances in Experimental Medicine and Biology*, **2022**, 1366, 15-26	3.6	
473	Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.. *Cell Discovery*, **2022**, 8, 36	22.3	4
472	Disease of influenza virus and SARS-CoV-2 coinfection: Flurona or Flucovid?. *Journal of Medical Virology*, **2022**,	19.7	0
471	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.. *Current Opinion in Virology*, **2021**, 53, 101199	7.5	0
470	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). *Cell Discovery*, **2021**, 7, 109	22.3	8
469	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. *Signal Transduction and Targeted Therapy*, **2021**, 6, 378	21	5

468	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
467	Antivirals with common targets against highly pathogenic viruses. *Cell*, **2021**, 184, 1604-1620	56.2	24
466	Dynamics of HIV-1 quasispecies diversity of participants on long-term antiretroviral therapy based on intrahost single-nucleotide variations. *International Journal of Infectious Diseases*, **2021**, 104, 306-314	10.5	3
465	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. *Signal Transduction and Targeted Therapy*, **2021**, 6, 132	21	17
464	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. *Nature Communications*, **2021**, 12, 1517	17.4	24
463	Immunoengineered adjuvants for universal vaccines against respiratory viruses. *Fundamental Research*, **2021**, 1, 189-192		1
462	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. *Stem Cell Reports*, **2021**, 16, 398-411	8	9
461	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. *Molecules*, **2021**, 26,	4.8	3
460	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human Coronavirus Infection. *Journal of Medicinal Chemistry*, **2021**,	8.3	1
459	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. *Microbes and Infection* , **2021**, 23, 104840	9.3	1
458	Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19. *Virologica Sinica*, **2021**, 36, 1080-1082	6.4	8
457	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. *Signal Transduction and Targeted Therapy*, **2021**, 6, 233	21	60
456	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. *Cell and Bioscience*, **2021**, 11, 128	9.8	2
455	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	12
454	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. *Journal of Medicinal Chemistry*, **2021**, 64, 11460-11471	8.3	2
453	Learning from the past: development of safe and effective COVID-19 vaccines. *Nature Reviews Microbiology*, **2021**, 19, 211-219	22.2	75
452	Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. *Cell Research*, **2021**, 31, 98-100	24.7	35
451	Long-term Survival of SARS-CoV-2 on Salmon as a Source for International Transmission. *Journal of Infectious Diseases*, **2021**, 223, 537-539	7	16

450	Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics. *Clinical and Translational Medicine*, **2021**, 11, e284	5.7	6
449	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. *Nature Communications*, **2021**, 12, 866	17.4	40
448	Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. *Clinical and Translational Medicine*, **2021**, 11, e331	5.7	3
447	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. *Cell Reports*, **2021**, 34, 108699	10.6	54
446	Double insult: flu bug enhances SARS-CoV-2 infectivity. *Cell Research*, **2021**, 31, 491-492	24.7	1
445	A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant. *Cell Reports*, **2021**, 36, 109401	10.6	1
444	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 288	21	13
443	FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat. *MBio*, **2021**, 12, e0079521	7.8	1
442	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. *Signal Transduction and Targeted Therapy*, **2021**, 6, 318	21	2
441	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	4
440	An ultrapotent pan-βcoronavirus lineage B (βCoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. *Protein and Cell*, **2021**, 1	7.2	2
439	Current Progress in the Development of Zika Virus Vaccines. *Vaccines*, **2021**, 9,	5.3	3
438	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in□vivo. *Immunity*, **2021**, 54, 2231-2244.e6	32.3	7
437	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Research*, **2021**, 31, 126-140	24.7	165
436	Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. *Emerging Microbes and Infections*, **2021**, 10, 439-441	18.9	2
435	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. *Protein and Cell*, **2021**, 12, 84-88	7.2	14
434	Neutralizing antibodies for the treatment of COVID-19. *Nature Biomedical Engineering*, **2020**, 4, 1134-1139	39	52
433	Current development of COVID-19 diagnostics, vaccines and therapeutics. *Microbes and Infection*, **2020**, 22, 231-235	9.3	34

432	From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. *Microbes and Infection*, **2020**, 22, 245-253	9.3	28
431	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. *Frontiers in Microbiology*, **2020**, 11, 1063	5.7	19
430	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. *Antiviral Research*, **2020**, 179, 104820	10.8	71
429	Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host and Microbe*, **2020**, 27, 891-898.e5	23.4	155
428	Development of small-molecule inhibitors against hantaviruses. *Microbes and Infection*, **2020**, 22, 272-277	9.3	
427	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. *Signal Transduction and Targeted Therapy*, **2020**, 5, 92	21	170
426	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. *Science Translational Medicine*, **2020**, 12,	17.5	5
425	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	23
424	Development of oncolytic virotherapy: from genetic modification to combination therapy. *Frontiers of Medicine*, **2020**, 14, 160-184	12	13
423	Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cellular and Molecular Immunology*, **2020**, 17, 613-620	15.4	910
422	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research*, **2020**, 30, 343-355	24.7	745
421	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. *ACS Infectious Diseases*, **2020**, 6, 882-890	5.5	6
420	Influenza virus glycoprotein-reactive human monoclonal antibodies. *Microbes and Infection*, **2020**, 22, 263-271	9.3	1
419	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerging Microbes and Infections*, **2020**, 9, 382-385	18.9	862
418	A distinct name is needed for the new coronavirus. *Lancet, The*, **2020**, 395, 949	40	216
417	Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. *Science*, **2020**, 367,	33.3	105
416	Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. *Frontiers in Microbiology*, **2020**, 11, 298	5.7	188
415	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cellular and Molecular Immunology*, **2020**, 17, 765-767	15.4	382

414	The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. *Virologica Sinica*, **2020**, 35, 263-265	6.4	41
413	Recent advances in the detection of respiratory virus infection in humans. *Journal of Medical Virology*, **2020**, 92, 408-417	19.7	233
412	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. *Microbes and Infection*, **2020**, 22, 74-79	9.3	220
411	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. *Virologica Sinica*, **2020**, 35, 340-343	6.4	8
410	Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. *Trends in Immunology* , **2020**, 41, 355-359	14.4	476
409	dl-Mandelic acid exhibits high sperm-immobilizing activity and low vaginal irritation: A potential non-surfactant spermicide for contraception. *Biomedicine and Pharmacotherapy*, **2020**, 126, 110104	7.5	3
408	Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. *Trends in Immunology*, **2020**, 41, 853-854	14.4	8
407	A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. *Signal Transduction and Targeted Therapy*, **2020**, 5, 71	21	16
406	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. *Cellular and Molecular Immunology*, **2020**, 17, 554	15.4	91
405	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerging Microbes and Infections*, **2020**, 9, 275-277	18.9	210
404	Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement **2020**,		23
403	Real-time imaging of individual virion-triggered cortical actin dynamics for human immunodeficiency virus entry into resting CD4 T cells. *Nanoscale*, **2020**, 12, 115-129	7.7	12
402	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. *Vaccine*, **2020**, 38, 7533-7541	4.1	50
401	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. *Virologica Sinica*, **2020**, 35, 857-860	6.4	17
400	Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein. *Signal Transduction and Targeted Therapy*, **2020**, 5, 220	21	21
399	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27141-27147	11.5	91
398	Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cellular and Molecular Immunology*, **2020**, 17, 894	15.4	56
397	PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF-Ƀ signaling. *EMBO Reports*, **2020**, 21, e49305	6.5	7

396	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. *Signal Transduction and Targeted Therapy*, **2020**, 5, 282	21	71
395	Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science*, **2020**, 369, 1603-1607	33.3	434
394	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. *Cell Research*, **2020**, 30, 932-935	24.7	73
393	Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines. *Vaccines*, **2020**, 8,	5.3	7
392	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. *Signal Transduction and Targeted Therapy*, **2020**, 5, 212	21	59
391	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Internal Medicine*, **2020**, 180, 1356-1362	11.5	152
390	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. *Frontiers in Pharmacology*, **2020**, 11, 613361	5.6	3
389	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. *Viruses*, **2019**, 11,	6.2	20
388	Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. *Viruses*, **2019**, 11,	6.2	7
387	The Underlying Mechanism of 3-Hydroxyphthalic Anhydride-Modified Bovine Beta-Lactoglobulin to Block Human Papillomavirus Entry Into the Host Cell. *Frontiers in Microbiology*, **2019**, 10, 2188	5.7	5
386	Design and Biological Evaluation of -Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. *Journal of Medicinal Chemistry*, **2019**, 62, 8773-8783	8.3	4
385	Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors. *Frontiers in Microbiology*, **2019**, 10, 1829	5.7	5
384	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. *Viruses*, **2019**, 11,	6.2	3
383	Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice. *European Journal of Pharmacology*, **2019**, 848, 62-69	5.3	21
382	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. *Cellular and Molecular Immunology*, **2019**, 16, 757-769	15.4	9
381	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. *Molecules*, **2019**, 24,	4.8	14
380	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Science Advances*, **2019**, 5, eaav4580	14.3	268
379	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. *Frontiers in Microbiology*, **2019**, 10, 29	5.7	10

378	Advances in the research and development of therapeutic antibodies against the Zika virus. *Cellular and Molecular Immunology*, **2019**, 16, 96-97	15.4	9
377	In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4. *Viruses*, **2019**, 11,	6.2	6
376	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. *Journal of Virology*, **2019**, 93,	6.6	4
375	N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein. *Frontiers in Pharmacology*, **2019**, 10, 859	5.6	12
374	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. *Frontiers in Microbiology*, **2019**, 10, 2250	5.7	5
373	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. *Viruses*, **2019**, 11,	6.2	26
372	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. *Aids*, **2019**, 33, 1545-1555	3.5	12
371	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. *PLoS Pathogens*, **2019**, 15, e1008082	7.6	7
370	Development of Small-Molecule Inhibitors Against Zika Virus Infection. *Frontiers in Microbiology*, **2019**, 10, 2725	5.7	23
369	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. *Biochemical and Biophysical Research Communications*, **2019**, 508, 1018-1023	3.4	17
368	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. *Viruses*, **2019**, 11,	6.2	20
367	Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. *Viruses*, **2019**, 11,	6.2	69
366	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. *Viruses*, **2019**, 11,	6.2	14
365	A natural "GA" insertion mutation in the sequence encoding the 3'UTR of CXCL12/SDF-1β Identification, characterization, and functional impact on mRNA splicing. *Gene*, **2019**, 681, 36-44	3.8	3
364	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. *European Journal of Pharmaceutical Sciences*, **2018**, 117, 313-320	5.1	7
363	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. *Vaccine*, **2018**, 36, 1853-1862	4.1	44
362	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. *Protein and Cell*, **2018**, 9, 596-615	7.2	26
361	Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. *Emerging Microbes and Infections*, **2018**, 7, 77	18.9	136

360	Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 2018-2026	8.3	30
359	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. *Emerging Microbes and Infections*, **2018**, 7, 7	18.9	30
358	Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application. *Critical Care Medicine*, **2018**, 46, e419-e425	1.4	14
357	A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. *Journal of Virology*, **2018**, 92,	6.6	62
356	Prospects for a MERS-CoV spike vaccine. *Expert Review of Vaccines*, **2018**, 17, 677-686	5.2	83
355	Reply to 'Trace N-glycans including sulphated species may originate from various plasma glycoproteins and not necessarily IgG'. *Nature Communications*, **2018**, 9, 2915	17.4	1
354	In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. *Frontiers in Immunology*, **2018**, 9, 128	8.4	16
353	3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor. *Frontiers in Microbiology*, **2018**, 9, 1330	5.7	3
352	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	46
351	Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains. *Molecules*, **2018**, 23,	4.8	3
350	A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. *Viruses*, **2018**, 10,	6.2	35
349	Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. *Nature Communications*, **2018**, 9, 2358	17.4	28
348	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. *Microbes and Infection*, **2018**, 20, 626-634	9.3	14
347	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. *Frontiers in Microbiology*, **2018**, 9, 2570	5.7	5
346	Development of Small-Molecule MERS-CoV Inhibitors. *Viruses*, **2018**, 10,	6.2	36
345	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. *Frontiers in Microbiology*, **2018**, 9, 2643	5.7	18
344	De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. *Journal of Medicinal Chemistry*, **2018**, 61, 8734-8745	8.3	27
343	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. *Aids*, **2018**, 32, 1749-1761	3.5	8

342	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. *Cellular and Molecular Immunology*, **2017**, 14, 568-571	15.4	2
341	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 707-719	6.8	19
340	Pathogenic Streptococcus strains employ novel escape strategy to inhibit bacteriostatic effect mediated by mammalian peptidoglycan recognition protein. *Cellular Microbiology*, **2017**, 19, e12724	3.9	4
339	Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice. *Scientific Reports*, **2017**, 7, 43373	4.9	26
338	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	15
337	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. *Emerging Microbes and Infections*, **2017**, 6, e59	18.9	17
336	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. *Aids*, **2017**, 31, 885-894	3.5	24
335	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. *EBioMedicine*, **2017**, 20, 193-201	8.8	40
334	Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. *Human Vaccines and Immunotherapeutics*, **2017**, 13, 1615-1624	4.4	43
333	Genome-wide analysis of an avirulent strain that induces protective immunity against challenge with virulent Streptococcus suis serotype 2. *BMC Microbiology*, **2017**, 17, 67	4.5	4
332	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. *Journal of Infection*, **2017**, 75, 68-71	18.9	6
331	MERS-CoV spike protein: a key target for antivirals. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 131-143	6.4	176
330	A Degraded Fragment of HIV-1 Gp120 in Rat Hepatocytes Forms Fibrils and Enhances HIV-1 Infection. *Biophysical Journal*, **2017**, 113, 1425-1439	2.9	7
329	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. *Cell Host and Microbe*, **2017**, 22, 471-483.e5	23.4	36
328	Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. *Microbes and Infection*, **2017**, 19, 641-647	9.3	12
327	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. *Microbes and Infection*, **2017**, 19, 597-604	9.3	10
326	A method to identify trace sulfated IgG N-glycans as biomarkers for rheumatoid arthritis. *Nature Communications*, **2017**, 8, 631	17.4	67
325	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. *Nature Communications*, **2017**, 8, 15672	17.4	83

324	Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. *Scientific Reports*, **2017**, 7, 6222	4.9	6
323	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. *Emerging Microbes and Infections*, **2017**, 6, e102	18.9	2
322	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. *Frontiers of Medicine*, **2017**, 11, 449-461	12	16
321	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. *Science China Life Sciences*, **2017**, 60, 1399-1402	8.5	23
320	Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. *Journal of Virology*, **2017**, 91,	6.6	58
319	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. *Journal of Virology*, **2017**, 91,	6.6	23
318	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. *Emerging Microbes and Infections*, **2017**, 6, e89	18.9	33
317	Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. *Molecules*, **2017**, 22,	4.8	11
316	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. *Frontiers in Immunology*, **2017**, 8, 1802	8.4	58
315	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. *BioMed Research International*, **2017**, 2017, 6096134	3	23
314	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. *Journal of Infection*, **2016**, 72, 123-5	18.9	
313	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. *Journal of Virology*, **2016**, 90, 57-67	6.6	64
312	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. *Nature Communications*, **2016**, 7, 13473	17.4	77
311	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. *Amino Acids*, **2016**, 48, 2867-2873	3.5	7
310	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. *Expert Opinion on Biological Therapy*, **2016**, 16, 1469-1478	5.4	11
309	Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases. *Journal of Biological Chemistry*, **2016**, 291, 24779-24786	5.4	29
308	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. *Scientific Reports*, **2016**, 6, 31983	4.9	11
307	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. *Scientific Reports*, **2016**, 6, 31629	4.9	42

306	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. *Scientific Reports*, **2016**, 6, 32161	4.9	8
305	A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. *Virology*, **2016**, 499, 375-382	3.6	76
304	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. *Cellular and Molecular Immunology*, **2016**, 13, 180-90	15.4	96
303	Vaccines for the prevention against the threat of MERS-CoV. *Expert Review of Vaccines*, **2016**, 15, 1123-34	5.2	64
302	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. *Chemical Science*, **2016**, 7, 2145-2150	9.4	5
301	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. *MAbs*, **2016**, 8, 761-74	6.6	16
300	A stereo configuration-activity study of 3-iodo-4-(2-methylcyclohexyloxy)-6-phenethylpyridin-2(2H)-ones as potency inhibitors of HIV-1 variants. *Organic and Biomolecular Chemistry*, **2016**, 14, 1413-20	3.9	4
299	Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2. *Archives of Virology*, **2016**, 161, 537-47	2.6	29
298	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. *Current Topics in Medicinal Chemistry*, **2016**, 16, 1074-90	3	49
297	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. *Aids*, **2016**, 30, 827-38	3.5	24
296	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. *Emerging Microbes and Infections*, **2016**, 5, e65	18.9	22
295	Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. *Journal of Medical Virology*, **2016**, 88, 1098-101	19.7	6
294	A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. *Reviews in Medical Virology*, **2016**, 26, 242-50	11.7	30
293	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. *Microbes and Infection*, **2016**, 18, 148-52	9.3	10
292	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. *Emerging Microbes and Infections*, **2016**, 5, e41	18.9	7
291	Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. *Journal of Medicinal Chemistry*, **2016**, 59, 3689-704	8.3	26
290	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. *Microbes and Infection*, **2015**, 17, 135-41	9.3	5
289	Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. *Clinical Infectious Diseases*, **2015**, 60, 586-95	11.6	48

288	A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein. *Vaccine*, **2015**, 33, 1974-80	4.1	10
287	Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. *Human Vaccines and Immunotherapeutics*, **2015**, 11, 1244-50	4.4	60
286	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). *Emerging Microbes and Infections*, **2015**, 4, e37	18.9	9
285	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. *Journal of Infectious Diseases*, **2015**, 212, 1894-903	7	71
284	In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations. *Human Vaccines and Immunotherapeutics*, **2015**, 11, 795-805	4.4	53
283	Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection. *Viruses*, **2015**, 7, 798-819	6.2	6
282	Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. *Journal of Virology*, **2015**, 89, 6121-5	6.6	129
281	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. *Journal of Virology*, **2015**, 89, 6960-4	6.6	15
280	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. *Lancet, The*, **2015**, 386, S44	40	3
279	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. *Future Virology*, **2015**, 10, 961-969	2.4	
278	Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines. *Human Vaccines and Immunotherapeutics*, **2015**, 11, 2831-8	4.4	6
277	The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4882-8	5.9	1
276	ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5123-34	5.9	15
275	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. *Nature Communications*, **2015**, 6, 8223	17.4	90
274	design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. *Chemical Science*, **2015**, 6, 6505-6509	9.4	8
273	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5115	11.5	1
272	Advancements in the development of subunit influenza vaccines. *Microbes and Infection*, **2015**, 17, 123-34	3.3	30
271	Development of therapeutics for treatment of Ebola virus infection. *Microbes and Infection*, **2015**, 17, 109-17	9.3	34

270	Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 159-73	6.8	22
269	Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 742-4	5.9	33
268	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. *Scientific Reports*, **2015**, 5, 13028	4.9	25
267	A Peptide Derived from the HIV-1 gp120 Coreceptor-Binding Region Promotes Formation of PAP248-286 Amyloid Fibrils to Enhance HIV-1 Infection. *PLoS ONE*, **2015**, 10, e0144522	3.7	11
266	Receptor binding domain based HIV vaccines. *BioMed Research International*, **2015**, 2015, 594109	3	4
265	Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. *Cancer Letters*, **2015**, 364, 79-88	9.9	48
264	Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. *Journal of Virology*, **2015**, 89, 9119-23	6.6	96
263	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. *Microbes and Infection*, **2015**, 17, 142-8	9.3	28
262	Receptor-binding domain-based subunit vaccines against MERS-CoV. *Virus Research*, **2015**, 202, 151-9	6.4	49
261	Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS ONE*, **2015**, 10, e0145561	3.7	59
260	Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin. *Oncotarget*, **2015**, 6, 29196-208	3.3	3
259	A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. *Current Pharmaceutical Design*, **2015**, 21, 925-35	3.3	14
258	Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. *Viruses*, **2015**, 8,	6.2	178
257	A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. *Journal of Virology*, **2014**, 88, 7045-53	6.6	112
256	Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *Journal of Virology*, **2014**, 88, 7796-805	6.6	182
255	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nature Communications*, **2014**, 5, 3067	17.4	247
254	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. *Biochimica Et Biophysica Acta - Biomembranes*, **2014**, 1838, 1296-305	3.8	22
253	Semen-mediated Enhancement of HIV Infection Markedly Impairs the Antiviral Efficacy of Microbicides. *AIDS Research and Human Retroviruses*, **2014**, 30, A183-A183	1.6	1

252	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. *Virus Research*, **2014**, 194, 200-10	6.4	79
251	Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. *ChemMedChem*, **2014**, 9, 1546-55	3.7	10
250	Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. *Vaccine*, **2014**, 32, 6170-6176	4.1	102
249	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1537-45	5.1	12
248	Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. *Journal of Medicinal Chemistry*, **2014**, 57, 7342-54	8.3	29
247	Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12516-21	11.5	182
246	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3719-23	2.9	6
245	CorMut: an R/Bioconductor package for computing correlated mutations based on selection pressure. *Bioinformatics*, **2014**, 30, 2073-5	7.2	8
244	Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection. *FEBS Letters*, **2014**, 588, 1515-22	3.8	17
243	FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model. *Microbes and Infection*, **2014**, 16, 409-18	9.3	4
242	Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. *Vaccine*, **2014**, 32, 2100-8	4.1	107
241	Studying the nucleated mammalian cell membrane by single molecule approaches. *PLoS ONE*, **2014**, 9, e91595	3.7	25
240	Current advancements and potential strategies in the development of MERS-CoV vaccines. *Expert Review of Vaccines*, **2014**, 13, 761-74	5.2	113
239	Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine. *Human Vaccines and Immunotherapeutics*, **2014**, 10, 3649-58	4.4	13
238	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. *Human Vaccines and Immunotherapeutics*, **2014**, 10, 648-58	4.4	82
237	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. *Laboratory Investigation*, **2014**, 94, 777-87	5.9	19
236	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. *Aids*, **2014**, 28, 1251-60	3.5	13
235	Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1 *Nucleic Acids Research*, **2014**, 42, 6578-90	20.1	60

234	Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 1-6	3.1	22
233	Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. *Science Translational Medicine*, **2014**, 6, 262ra157	17.5	53
232	Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models. *PLoS ONE*, **2014**, 9, e92987	3.7	15
231	Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains. *PLoS ONE*, **2014**, 9, e93804	3.7	6
230	Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. *Virology Journal*, **2013**, 10, 10	6.1	13
229	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. *Journal of Infection*, **2013**, 67, 156-8	18.9	6
228	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2533-44	5.1	29
227	Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. *American Journal of Respiratory Cell and Molecular Biology*, **2013**, 49, 221-30	5.7	71
226	Receptor binding and transmission studies of H5N1 influenza virus in mammals. *Emerging Microbes and Infections*, **2013**, 2, e85	18.9	10
225	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. *Microbes and Infection*, **2013**, 15, 506-10	9.3	15
224	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. *Virology Journal*, **2013**, 10, 266	6.1	102
223	Isolation of Anti-HIV Components from Canarium album Fruits by High-Speed Counter-Current Chromatography. *Analytical Letters*, **2013**, 46, 1057-1068	2.2	10
222	Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. *Journal of Virology*, **2013**, 87, 2215-25	6.6	28
221	F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. *Microbes and Infection*, **2013**, 15, 887-94	9.3	3
220	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: potential implication for animal surveillances. *Journal of Infection*, **2013**, 67, 490-4	18.9	17
219	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. *Journal of Infection*, **2013**, 66, 464-6	18.9	34
218	Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 2527-39	8.3	20
217	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains. *Journal of Medicinal Chemistry*, **2013**, 56, 3593-608	8.3	27

216	Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 7539-48	3.4	23
215	Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. *Microbes and Infection*, **2013**, 15, 432-9	9.3	67
214	3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4. *AIDS Research and Human Retroviruses*, **2013**, 29, 1455-64	1.6	4
213	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. *Microbes and Infection*, **2013**, 15, 625-9	9.3	59
212	Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. *Journal of Infection*, **2013**, 67, 348-50	18.9	16
211	Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodies. *Journal of Infectious Diseases*, **2013**, 208, 1315-9	7	5
210	Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. *Viruses*, **2013**, 5, 127-49	6.2	39
209	Respiratory syncytial virus entry inhibitors targeting the F protein. *Viruses*, **2013**, 5, 211-25	6.2	52
208	Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. *Clinical Infectious Diseases*, **2013**, 57, 919-21	11.6	14
207	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. *Journal of Virology*, **2013**, 87, 9939-42	6.6	140
206	Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2521-4	5.1	8
205	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 573-6	5.1	9
204	A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. *PLoS ONE*, **2013**, 8, e53568	3.7	24
203	HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]. *PLoS ONE*, **2013**, 8, e54452	3.7	17
202	Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. *PLoS ONE*, **2013**, 8, e59777	3.7	30
201	Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. *PLoS ONE*, **2013**, 8, e66156	3.7	6
200	A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. *PLoS ONE*, **2013**, 8, e81587	3.7	126
199	Simultaneous expression of displayed and secreted antibodies for antibody screen. *PLoS ONE*, **2013**, 8, e80005	3.7	5

198	Receptor-binding domain as a target for developing SARS vaccines. *Journal of Thoracic Disease*, **2013**, 5 Suppl 2, S142-8	2.6	41
197	Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2393-5	2.9	9
196	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3284-6	2.9	17
195	Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV). *Virus Genes*, **2012**, 45, 218-24	2.3	1
194	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. *Chemical Communications*, **2012**, 48, 11579-81	5.8	14
193	Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway. *Vaccine*, **2012**, 30, 5733-9	4.1	27
192	Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses. *Reviews in Medical Virology*, **2012**, 22, 412-9	11.7	3
191	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. *Retrovirology*, **2012**, 9, 104	3.6	49
190	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. *Expert Review of Vaccines*, **2012**, 11, 1405-13	5.2	93
189	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. *Biochimica Et Biophysica Acta - Biomembranes*, **2012**, 1818, 2950-7	3.8	26
188	Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission. *AIDS Research and Human Retroviruses*, **2012**, 28, 1498-508	1.6	14
187	Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. *PLoS ONE*, **2012**, 7, e37381	3.7	26
186	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. *Journal of Medicinal Chemistry*, **2012**, 55, 2242-50	8.3	32
185	A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. *Fitoterap*, **2012**, 83, 348-55	3.2	39
184	Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor. *Cellular and Molecular Immunology*, **2012**, 9, 184-90	15.4	14
183	What can academia learn from XMRV studies?. *Nature Reviews Urology*, **2012**, 9, 174; author reply 174	5.5	2
182	Biosecurity and biosafety in research on emerging pathogens. *Emerging Microbes and Infections*, **2012**, 1, e44	18.9	4
181	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. *Emerging Microbes and Infections*, **2012**, 1, e13	18.9	33

180	Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. *Journal of Virology*, **2012**, 86, 589-93	6.6	21
179	L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 3121-32	5.9	11
178	Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination. *FASEB Journal*, **2012**, 26, 1018-26	0.9	15
177	Biorisk management in studies of highly pathogenic H5N1 viruses. *Future Virology*, **2012**, 7, 637-639	2.4	
176	The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. *PLoS ONE*, **2012**, 7, e37019	3.7	26
175	The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. *PLoS ONE*, **2012**, 7, e44874	3.7	5
174	Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. *Journal of Medicinal Chemistry*, **2011**, 54, 572-9	8.3	63
173	A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. *PLoS ONE*, **2011**, 6, e16555	3.7	31
172	Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. *PLoS ONE*, **2011**, 6, e17605	3.7	23
171	HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. *PLoS ONE*, **2011**, 6, e18233	3.7	30
170	Pathogenesis and treatment of human immunodeficiency virus-associated cytomegalovirus retinitis. *Future Virology*, **2011**, 6, 503-520	2.4	1
169	Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. *Journal of Visualized Experiments*, **2011**,	1.6	5
168	CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry. *European Journal of Pharmacology*, **2011**, 660, 460-7	5.3	51
167	Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 6726-34	3.4	38
166	Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6895-8	2.9	25
165	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro. *European Journal of Medicinal Chemistry*, **2011**, 46, 1701-5	6.8	6
164	An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation. *ChemMedChem*, **2011**, 6, 1654-64	3.7	10
163	Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold. *ChemBioChem*, **2011**, 12, 2647-58	3.8	10

162	HIV-associated dementia in the era of highly active antiretroviral therapy (HAART). *Microbes and Infection*, **2011**, 13, 419-25	9.3	20
161	Four-way ligation for construction of a mammalian cell-based full-length antibody display library. *Acta Biochimica Et Biophysica Sinica*, **2011**, 43, 232-8	2.8	5
160	In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2011**, 286, 3277-87	5.4	41
159	Complement inhibition alleviates paraquat-induced acute lung injury. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 834-42	5.7	31
158	A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. *Journal of Biological Chemistry*, **2011**, 286, 28425-34	5.4	13
157	HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection. *Journal of Biological Chemistry*, **2011**, 286, 44869-77	5.4	7
156	HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. *Biochemical Journal*, **2011**, 438, 457-66	3.8	10
155	Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 56, 384-92	3.1	9
154	Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. *PLoS ONE*, **2010**, 5, e9549	3.7	76
153	A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. *Viral Immunology*, **2010**, 23, 211-9	1.7	40
152	Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. *Journal of Biological Chemistry*, **2010**, 285, 25506-15	5.4	43
151	HIV type 1 B'/C recombinant (CRF07_BC) in virologic noncontrollers elicits neutralizing antibodies against heterologous but not autologous viruses. *AIDS Research and Human Retroviruses*, **2010**, 26, 237-9	1.6	2
150	Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. *Journal of Virology*, **2010**, 84, 9359-68	6.6	16
149	A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces. *Acta Biochimica Et Biophysica Sinica*, **2010**, 42, 575-84	2.8	12
148	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 4906-16	8.3	38
147	An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. *Virology Journal*, **2010**, 7, 151	6.1	30
146	Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. *Virology Journal*, **2010**, 7, 299	6.1	52
145	An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. *Virology Journal*, **2010**, 7, 9	6.1	72

144	Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. *Biochemical and Biophysical Research Communications*, **2010**, 397, 580-5	3.4	28
143	A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. *Biochemical and Biophysical Research Communications*, **2010**, 398, 506-12	3.4	21
142	Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. *Vaccine*, **2010**, 28, 7233-40	4.1	28
141	Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 8287-97	8.3	41
140	HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. *Journal of the Formosan Medical Association*, **2010**, 109, 94-105	3.2	50
139	Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. *MAbs*, **2010**, 2, 266-74	6.6	19
138	3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1700-11	5.9	27
137	Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. *Protein and Cell*, **2010**, 1, 342-354	7.2	21
136	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. *Retrovirology*, **2010**, 7, 37	3.6	20
135	Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. *ChemMedChem*, **2010**, 5, 1813-24	3.7	76
134	Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population. *Journal of Medical Virology*, **2010**, 82, 371-8	19.7	37
133	Research and development of universal influenza vaccines. *Microbes and Infection*, **2010**, 12, 280-6	9.3	88
132	Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. *Bioorganic and Medicinal Chemistry Letters*, **2010** , 20, 189-92	2.9	36
131	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. *European Journal of Medicinal Chemistry*, **2010**, 45, 4096-103	6.8	11
130	Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41. *Acta Crystallographica Section F: Structural Biology Communications*, **2010**, 66, 854-7		1
129	Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site. *Future Microbiology*, **2009**, 4, 507-9	2.9	2
128	Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. *Journal of Immunology*, **2009**, 182, 4005-16	5.3	31
127	Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. *Journal of Virology*, **2009**, 83, 7862-72	6.6	45

126	ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 4987-98	5.9	48
125	Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. *Virology*, **2009**, 393, 144-50	3.6	93
124	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. *Science Bulletin*, **2009**, 54, 1707-1712	10.6	
123	The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nature Reviews Microbiology*, **2009**, 7, 226-36	22.2	1007
122	Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5482-5	2.9	24
121	Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. *Biochemical and Biophysical Research Communications*, **2009**, 384, 486-90	3.4	41
120	High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission. *Biochemical and Biophysical Research Communications*, **2009**, 385, 402-7	3.4	8
119	Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. *Immunobiology*, **2009**, 214, 51-60	3.4	16
118	Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. *Retrovirology*, **2009**, 6, 45	3.6	27
117	Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 7631-9	8.3	86
116	Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. *Aids*, **2009**, 23, 639-41	3.5	34
115	Prolongation of corneal xenotransplant survival by T-cell vaccination-induced T-regulatory cells. *Xenotransplantation*, **2008**, 15, 164-73	2.8	8
114	Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. *Journal of Medicinal Chemistry*, **2008**, 51, 7843-54	8.3	99
113	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK). *Journal of Medicinal Chemistry*, **2008**, 51, 7689-96	8.3	19
112	Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. *Vaccine*, **2008**, 26, 1644-51	4.1	67
111	Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. *Vaccine*, **2008**, 26, 5022-9	4.1	12
110	Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs. *Biochemical and Biophysical Research Communications*, **2008**, 374, 767-72	3.4	11
109	Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. *Biochemical and Biophysical Research Communications*, **2008**, 376, 60-4	3.4	4

108	Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2008**, 283, 11126-34	5.4	169
107	Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16332-7	11.5	118
106	Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. *Journal of Biological Chemistry*, **2008**, 283, 30376-84	5.4	44
105	Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV. *Journal of Biological Chemistry*, **2008**, 283, 14994-5002	5.4	12
104	Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. *Journal of Virology*, **2008**, 82, 6869-79	6.6	38
103	Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. *Journal of Immunology*, **2008**, 180, 948-56	5.3	102
102	The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. *FASEB Journal*, **2008**, 22, 1179-92	0.9	17
101	Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. *Journal of Biological Chemistry*, **2008**, 283, 16723-31	5.4	37
100	Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. *Journal of Virology*, **2008**, 82, 6349-58	6.6	76
99	Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. *Journal of Virology*, **2008**, 82, 11129-39	6.6	57
98	Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 3039-48	3.4	61
97	Development of subunit vaccines against severe acute respiratory syndrome. *Drugs of Today*, **2008**, 44, 63-73	2.5	21
96	Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. *Biochemical and Biophysical Research Communications*, **2007**, 359, 174-9	3.4	96
95	Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity. *European Journal of Pharmacology*, **2007**, 565, 54-9	5.3	16
94	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 12123-8	11.5	246
93	HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. *Current Pharmaceutical Design*, **2007**, 13, 143-62	3.3	123
92	HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. *Journal of Biological Chemistry*, **2007**, 282, 9612-9620	5.4	115
91	Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. *Journal of Biological Chemistry*, **2007**, 282, 6143-52	5.4	39

90	Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. *Journal of Biological Chemistry*, **2007**, 282, 25631-9	5.4	71
89	The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. *Biochemical Journal*, **2007**, 403, 565-71	3.8	16
88	Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine*, **2007**, 25, 2832-8	4.1	128
87	HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC. *Biochemical and Biophysical Research Communications*, **2007**, 356, 899-905	3.4	12
86	Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. *Cell* , **2007**, 129, 263-75	56.2	206
85	Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. *Journal of Hepatology*, **2007**, 46, 198-205	13.4	34
84	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. *Virology*, **2006**, 353, 6-16	3.6	38
83	Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. *Virology*, **2006**, 352, 74-85	3.6	6
82	Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. *Journal of Immunological Methods*, **2006**, 317, 21-30	2.5	32
81	Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 1393-401	5.9	59
80	Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. *Journal of Virology*, **2006**, 80, 5757-67	6.6	92
79	Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. *Journal of Immunology*, **2006**, 176, 6085-92	5.3	93
78	Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. *Journal of Biological Chemistry*, **2006**, 281, 18787-92	5.4	109
77	China needs safe and effective microbicides for preventing sexual transmission of HIV. *Lancet Infectious Diseases, The*, **2006**, 6, 681-2	25.5	0
76	Microbicides: stopping HIV at the gate. *Lancet, The*, **2006**, 368, 431-3	40	24
75	Identification of the HIV-1 gp41 core-binding motif--HXXNPF. *FEBS Letters*, **2006**, 580, 4807-14	3.8	16
74	Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. *ACS Combinatorial Science*, **2006**, 8, 531-9		33
73	The ribosomal protein L32-2 (RPL32-2) of S. pombe exhibits a novel extraribosomal function by acting as a potential transcriptional regulator. *FEBS Letters*, **2006**, 580, 1827-32	3.8	7

72	A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. *Biochemical and Biophysical Research Communications*, **2006**, 344, 106-13	3.4	25
71	Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. *Biochemical and Biophysical Research Communications*, **2006**, 347, 909-15	3.4	6
70	Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. *Vaccine*, **2006**, 24, 5498-508	4.1	46
69	Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. *Immunobiology*, **2005**, 210, 639-45	3.4	10
68	Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. *Biochimica Et Biophysica Acta - General Subjects*, **2005**, 1723, 270-81	4	117
67	rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. *Vaccine*, **2005**, 23, 3446-52	4.1	26
66	Vaccine design for severe acute respiratory syndrome coronavirus. *Viral Immunology*, **2005**, 18, 327-32	1.7	32
65	Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. *Virology*, **2005**, 334, 74-82	3.6	97
64	Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. *Virology*, **2005**, 339, 213-25	3.6	178
63	Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. *ChemBioChem*, **2005**, 6, 1068-74	3.8	58
62	SARS vaccine development. *Emerging Infectious Diseases*, **2005**, 11, 1016-20	10.2	126
61	Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. *Journal of Immunology*, **2005**, 174, 4908-15	5.3	202
60	Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. *Journal of Biological Chemistry*, **2005**, 280, 11259-73	5.4	183
59	Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1830-6	5.9	60
58	Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. *Journal of Clinical Microbiology*, **2005**, 43, 3718-26	9.7	67
57	SARS Vaccine Development. *Emerging Infectious Diseases*, **2005**, 11, 1016-1020	10.2	149
56	Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. *Journal of Immunology*, **2004**, 173, 4050-7	5.3	128
55	Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. *Journal of Virology*, **2004**, 78, 2627-31	6.6	84

54	Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. *Journal of Clinical Microbiology*, **2004**, 42, 5309-14	9.7	50
53	Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *Journal of Pathology*, **2004**, 203, 622-30	9.4	722
52	Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 1215-20	3.4	19
51	N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 4349-59	5.9	224
50	Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochemical and Biophysical Research Communications*, **2004**, 324, 773-81	3.4	316
49	Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. *Biochemical and Biophysical Research Communications*, **2004**, 325, 445-52	3.4	109
48	Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. *Lancet, The*, **2004** , 363, 938-47	40	380
47	High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. *Current Pharmaceutical Design*, **2004**, 10, 1827-43	3.3	45
46	Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. *AIDS Research and Human Retroviruses*, **2003**, 19, 947-55	1.6	13
45	Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. *Journal of Virological Methods*, **2003**, 107, 155-61	2.6	16
44	Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. *Peptides*, **2003**, 24, 1303-13	3.8	63
43	Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. *Biochemistry*, **2003**, 42, 14150-8	3.2	52
42	Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. *Journal of Biomolecular Screening*, **2003**, 8, 685-93		47
41	Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. *Angewandte Chemie - International Edition*, **2002**, 41, 278-81	16.4	146
40	Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. *BMC Infectious Diseases*, **2002**, 2, 6	4	53
39	XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. *AIDS Research and Human Retroviruses*, **2002**, 18, 989-97	1.6	38
38	Peptide and non-peptide HIV fusion inhibitors. *Current Pharmaceutical Design*, **2002**, 8, 563-80	3.3	107
37	The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. *Biochemical and Biophysical Research Communications*, **2002**, 298, 552-8	3.4	45

36	Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. *Life Sciences*, **2002**, 71, 1779-91	6.8	32
35	Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. *Biochemical and Biophysical Research Communications*, **2000**, 269, 641-6	3.4	49
34	A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. *Biochemical and Biophysical Research Communications*, **2000** , 270, 153-7	3.4	54
33	N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. *Clinical Immunology*, **2000**, 96, 236-42	9	32
32	Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. *Biochemistry*, **2000**, 39, 1634-42	3.2	71
31	Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. *Biologicals*, **1999**, 27, 11-21	1.8	47
30	A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. *Journal of Virological Methods*, **1999**, 80, 85-96	2.6	99
29	Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. *Journal of Medicinal Chemistry*, **1999**, 42, 3203-9	8.3	147
28	HIV-1--co-receptors binding. *Nature Medicine*, **1997**, 3, 367-8	50.5	31
27	A herpesvirus inhibitor from bovine whey. *Lancet, The*, **1996**, 347, 1703-1704	40	13
26	Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. *Nature Medicine*, **1996**, 2, 230-4	50.5	69
25	Chemically modified bovine beta-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines. *Journal of Acquired Immune Deficiency Syndromes*, **1996**, 13, 461-2		13
24	Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. *Journal of Molecular Recognition*, **1995**, 8, 304-16	2.6	29
23	A complex aetiological connotation of acute non-A, non-B hepatitis in China. *Journal of Hepatology*, **1994**, 21, 916	13.4	1
22	Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. *Journal of Medicinal Chemistry*, **1994**, 37, 1099-108	8.3	72
21	Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. *AIDS Research and Human Retroviruses*, **1993**, 9, 1195-208	1.6	5
20	Etiological investigation of acute post-transfusion non-A, non-B hepatitis in China. *Journal of Medical Virology*, **1993**, 39, 219-23	19.7	6
19	HIV-1 inhibition by a peptide. *Nature*, **1993**, 365, 113	50.4	425

18	Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. *Immunological Investigations*, **1992**, 21, 275-81	2.9	5
17	Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. *Journal of Medical Virology*, **1991**, 35, 55-9	19.7	58
16	Plasma membrane-associated proteins with the ability to partially inhibit perforin-mediated lysis. *Immunology Letters*, **1991**, 28, 101-8	4.1	21
15	Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. *AIDS Research and Human Retroviruses*, **1991**, 7, 813-23	1.6	22
14	Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies. *AIDS Research and Human Retroviruses*, **1991**, 7, 657-62	1.6	9
13	Cytoplasts from cytotoxic T lymphocytes are resistant to perforin-mediated lysis. *Molecular Immunology*, **1991**, 28, 1011-8	4.3	18
12	Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor. *Journal of Immunological Methods*, **1990**, 128, 133-42	2.5	1
11	Resistance to the pore-forming protein of cytotoxic T cells: comparison of target cell membrane rigidity. *Molecular Immunology*, **1990**, 27, 839-45	4.3	7
10	The lymphocyte pore-forming protein perforin is associated with granules by a pH-dependent mechanism. *Immunology Letters*, **1989**, 22, 23-7	4.1	15
9	Differential susceptibility of type III erythrocytes of paroxysmal nocturnal hemoglobinuria to lysis mediated by complement and perforin. *Biochemical and Biophysical Research Communications*, **1989**, 162, 316-25	3.4	12
8	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody		2
7	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies		1
6	Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion		4
5	Fully human single-domain antibodies against SARS-CoV-2		10
4	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications		282
3	Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy		20
2	Engineered Trimeric ACE2 Binds and Locks Three-up Spike Protein to Potently Inhibit SARS-CoVs and Mutants		2
1	Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis		19